Saúde Pública/Medicina Humanitária
Estudo observacional no Catar mostrou que a efetividade da vacina da Pfizer contra qualquer infecção por SARS-CoV-2 caiu para 20% entre o 5º e o 7º mês após a segunda dose, mas a efetividade contra Covid-19 grave permaneceu alta.
8 Out, 2021 | 12:04h
Comentário no Twitter
In this 900,000-participant study in Qatar, vaccine effectiveness peaked at 77.5% in the first month after the second dose. The effectiveness fell to as low as 20% in months 5 through 7 after vaccination. #Covid19vaccine #IDTwttier https://t.co/TeDcLLftIH pic.twitter.com/pEBoxs6Hmr
— NEJM (@NEJM) October 6, 2021
Amplo estudo de coorte com mais de 2.5 milhões de indivíduos mostrou que a incidência de miocardite após a vacina da Pfizer foi de 2,13 casos por 100.000 pessoas.
8 Out, 2021 | 12:02hComentário: Studies Highlight Rarity of Myocarditis With mRNA COVID-19 Vaccines – TCTMD
Estudo relacionado: Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel – New England Journal of Medicine
Comentários no Twitter
Among 2.5 million patients who received the BNT162b2 mRNA vaccine in a large Israeli health care system, the incidence of myocarditis at 42 days was 2.13 cases per 100,000 persons. #Covid19vaccine #IDTwitter https://t.co/EzmsaW2u4Y pic.twitter.com/P95eUm8xo9
— NEJM (@NEJM) October 6, 2021
Just out in @NEJM: Two studies on myocarditis after vaccination with Pfizer
Among 2.5 million vaccinated:
– 54 cases of myocarditis
– 94% men, median 27 y.o.
– Most cases mild, only one fulminanthttps://t.co/xGf7rtwGfr— David Juurlink (@DavidJuurlink) October 6, 2021
Estudo com mais de 5,1 milhões de indivíduos vacinados mostrou que a incidência de miocardite após receberem a vacina da Pfizer foi baixa e mais comum após a segunda dose em homens jovens.
8 Out, 2021 | 12:00hMyocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel – New England Journal of Medicine
Comentário: Studies Highlight Rarity of Myocarditis With mRNA COVID-19 Vaccines – TCTMD
Estudo relacionado: Myocarditis after Covid-19 Vaccination in a Large Health Care Organization – New England Journal of Medicine
Comentários no Twitter
In an Israeli Ministry of Health database, 136 cases of myocarditis were detected among 5 million vaccinated persons. #Covid19vaccine #IDTwitter https://t.co/c1wLBCq8UN pic.twitter.com/D2DAGrIuXe
— NEJM (@NEJM) October 6, 2021
Two new @NEJM reports on Pfizer vaccine related myocarditis: very rare (~2 per 100,000) and usually mild; in-depth review of 190 cases, most cases were in males 16-29 years, 2nd dosehttps://t.co/nHgxXTgQ6ohttps://t.co/pchL0VDi4b pic.twitter.com/7pUxNy36Zo
— Eric Topol (@EricTopol) October 6, 2021
Perspectiva | Ninguém está seguro até que todos estejam.
8 Out, 2021 | 11:59hNo one is safe until we are all safe – Science Translational Medicine
Comentário: Covid ‘still running rampant’ worldwide, warns creator of Oxford vaccine – The Guardian
Conteúdo relacionado: Opinion: Vaccine Nationalism Harms Everyone and Protects No One
Comentário no Twitter
No one is safe until we all are safe, by Sarah Gilbert @JennerInstitute @NDMOxford @UniofOxford and @DrRHatchett @CEPIVaccines
With a forecast of global vaccine supply for 2021https://t.co/iUgC6euvz6 @ScienceTM a large proportion are Sinopharm and Sinovac from China pic.twitter.com/w4KfUAsU45— Eric Topol (@EricTopol) October 6, 2021
Suécia e Dinamarca pausam o uso da vacina da Moderna contra COVID-19 em grupos jovens.
8 Out, 2021 | 11:57hSweden, Denmark pause Moderna COVID-19 vaccine for younger age groups – Reuters
OMS aprova a primeira vacina contra malária para crianças em risco.
8 Out, 2021 | 11:56hWHO recommends groundbreaking malaria vaccine for children at risk – World Health Organization
Comentários:
WHO Approves First Ever Malaria Vaccine – Health Policy Watch
In major decision, WHO recommends broad rollout of world’s first malaria vaccine – STAT
Why the WHO approval of the first malaria vaccine is a big deal – Vox
WHO greenlights the world’s first malaria vaccine — but it’s not a perfect shot – NPR
The World Health Organization Just Endorsed The World’s First Malaria Vaccine – TIME
WHO Backs Widespread Use Of First Malaria Vaccine – Forbes
World’s 1st malaria vaccine recommended by WHO – LiveScience
Comentários no Twitter
I started my career as a #malaria researcher, and I longed for the day that we would have an effective vaccine against this ancient and terrible disease. Today is that day: @WHO is recommending the broad use of the world’s first malaria vaccine. #EndMalaria https://t.co/Oh1O155tYj
— Tedros Adhanom Ghebreyesus (@DrTedros) October 6, 2021
(fio – clique para saber mais)
A child dies from #malaria every two minutes.
One death is one too many.🚨 Today, WHO recommends RTS,S, a groundbreaking malaria vaccine, to reduce child illness & deaths in areas with moderate and high malaria transmission https://t.co/xSk58nTIV1#VaccinesWork pic.twitter.com/mSECLtRhQs
— World Health Organization (WHO) (@WHO) October 6, 2021
Revisão sistemática | Administração de medicamentos antimaláricos para populações inteiras visando à redução da malária.
8 Out, 2021 | 11:53hAdministration of antimalarial drugs to whole populations for reducing malaria – Cochrane Library
Estudo original: Mass drug administration for malaria – Cochrane Library
Comentário no Twitter
Administration of #antimalarial drugs to whole populations for reducing #malaria – https://t.co/4Q4vGKwmgU – Updated #OpenAccess @Cochrane_IDG review includes 13 studies and gives implications for practice & future research. pic.twitter.com/EMB2Tihs81
— Cochrane UK (@CochraneUK) October 3, 2021
Comissão Lancet | Transformando acesso em diagnóstico.
8 Out, 2021 | 11:50hComunicado de imprensa: The Lancet: Half of the global population lack access to basic diagnostics for many common diseases
Vídeo: Transforming access to diagnostics | The Lancet Commission on diagnostics
Página principal: The Lancet Commission on diagnostics: transforming access to diagnostics
The Lancet Commission on diagnostics: transforming access to diagnostics (necessário cadastro gratuito)
Transforming access to diagnostics: how to turn good intentions into action? (necessário cadastro gratuito)
Can COVID-19 help accelerate and transform the diagnostics agenda?
Comentário: A Grim Diagnosis – Half The World’s Population Has Limited Access To Diagnostics – Forbes
Conteúdos relacionados:
WHO Updates Global Guidance on Medicines and Diagnostic Tests
The WHO Essential Diagnostic List: A Tool for the Future
Perspective: Health Care is an Essential Human Right – And So Is a Proper Diagnosis
Report: First-ever WHO List of Essential Diagnostic Tests
Comentário no Twitter
The #DiagnosticsCommission is now LIVE on @TheLancet. Visit our website to read the report and to register for our Launch event tomorrow. @FINDdx https://t.co/V3M6IRI7cG pic.twitter.com/hqoJlIwwh5
— Diagnostics Commission (@DiagnosticsCom) October 6, 2021
Choosing Wisely | Sete perguntas que médicos e residentes/pacientes deveriam fazer nos cuidados de longo prazo.
8 Out, 2021 | 11:48hVer listas completas de práticas de baixo valor: Choosing Wisely U.S. / Choosing Wisely UK / Choosing Wisely Australia E Choosing Wisely Canada
Recomendações da EMA sobre doses extras e de reforço das vacinas mRNA da BioNTech/Pfizer e da Moderna.
8 Out, 2021 | 11:26hComirnaty and Spikevax: EMA recommendations on extra doses and boosters – European Medicines Agency
Conteúdo relacionado: The difference between COVID-19 ‘third doses’ and ‘boosters’ – Emory News Center
Comentário no Twitter
EMA recommended additional doses and boosters for #Comirnaty and #Spikevax. https://t.co/qefPg2kMMO
In this context, see below what the difference between an additional dose and a #boosterdose is. pic.twitter.com/HeyOACbWXm
— EU Medicines Agency (@EMA_News) October 5, 2021